Agios Pharmaceuticals, Inc.
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 8.6% | 28.0% | 24.1% | 35.8% | 8.7% | 11.7% | 27.1% | 23.8% | 23.7% | 15.8% | 12.9% | 6.7% | 12.1% | |
| 91.4% | 72.0% | 75.9% | 64.2% | 91.3% | 88.3% | 72.9% | 76.2% | 76.3% | 84.2% | 87.1% | 93.3% | 87.9% | |
| 1,106.1% | 1,071.2% | 821.5% | 880.0% | 808.3% | 771.8% | 819.0% | 728.1% | 663.2% | 434.7% | 384.6% | 225.2% | 358.7% | |
| 349.0% | 497.0% | 378.7% | 412.5% | 429.9% | 481.8% | 475.9% | 368.3% | 320.5% | 258.5% | 232.8% | 115.2% | 196.0% | |
| 1,455.1% | 1,568.2% | 1,200.2% | 1,292.4% | 1,238.2% | 1,253.6% | 1,294.9% | 1,096.3% | 983.7% | 693.1% | 617.4% | 340.4% | 554.7% | |
| -1,363.7% | -1,496.2% | -1,124.3% | -1,228.3% | -1,146.9% | -1,165.3% | -1,222.0% | -1,020.1% | -907.4% | -608.9% | -530.3% | -247.1% | -466.8% | |
| -1,234.3% | -1,350.7% | -995.8% | -1,115.7% | 11,167.3% | -982.3% | -1,023.3% | -899.4% | -803.1% | -546.2% | -477.7% | -225.1% | -419.3% | |
| -135.1% | 19.1% | 15.9% | – | 592.6% | -82.7% | – | – | – | -5.1% | – | – | – | |
| -1,234.3% | -1,350.7% | -995.8% | -1,115.7% | 10,574.7% | -899.6% | -1,023.3% | -899.4% | -803.1% | -541.1% | -477.7% | -225.1% | -418.2% | |
| -1,212.3% | -1,330.9% | -979.4% | -1,097.2% | 11,182.3% | -969.5% | -1,008.6% | -889.3% | -792.4% | -539.8% | -471.2% | -244.1% | -423.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.